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Abstract
AIM: To study whether immune-activation stage in se-
rum of adult Crohn’s disease (CD) patients correlates 
with disease activity and with treatment response to anti-
tumor necrosis factor-α (TNF-α) therapy. 
METHODS: Serum samples were obtained from 15 
adult CD patients introduced to anti-TNF-α therapy. The 
individual stage of immune activation was studied ap-
plying our new in vitro  assay, in which target cells (do-
nor derived peripheral blood mononuclear cells) were 
cultured with patient serum and the T-cell activation in-
duced by the patient serum was studied using a panel 
of markers for effector [interferon γ (IFNγ), interleukin 
(IL)-5] and regulatory T-cells [forkhead transcription 
factor 3 (FOXP3) and glucocorticoid-induced tumour 
necrosis factor receptor (GITR)]. The endoscopic dis-
ease activity was assessed with the Crohn’s disease 
endoscopic index of severity (CDEIS) before and 3 mo 
after therapy with an anti-TNF-α agent. 
RESULTS: Low induction of FOXP3 and GITR in target 
cells cultured in the presence of patient serum was as-
sociated with high disease activity i.e. CDEIS assessed 
before therapy (r  = -0.621, P  = 0.013 and r  = -0.625, 
P  = 0.013, respectively). FOXP3 expression correlated 
inversely with pre-treatment erythrocyte sedimentation 
rate (r  = -0.548, P  = 0.034). Low serum induced FOXP3 
(r  = -0.600, P = 0.018) and GITR (r  = -0.589, P = 0.021) 
expression and low IFNγ secretion from target cells (r  = 
-0.538, P  = 0.039) associated with treatment response 
detected as a decrease in CDEIS. 
CONCLUSION: The immune-activation potency in the 
patient serum prior to anti-TNF-α therapy reflected in-
testinal inflammation and the therapeutic response.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Tumor necrosis factor-α (TNF-α), a pro-inflammatory 
protein secreted mainly by monocytes, macrophages and 
T-cells, has a central role in the disease pathogenesis of  
Crohn’s disease (CD)[1-3]. TNF-α is elevated in stools and 
mucosa of  CD patients[4-6]. 
The chimeric TNF-α-antibody infliximab and human 
IgG1 TNF-α-antibody adalimumab are indicated for the 
treatment of  moderate to severe CD[7,8]. During treatment 
with an anti-TNF-α agent, clinical improvement is accom-
panied by significant healing of  endoscopic lesions and 
the disappearance of  mucosal inflammatory infiltrate[9]. 
The therapeutic response, however, is not uniform and 
a significant proportion of  patients are non-responders. 
In the ACCENT I study, 58% of  patients with moderate 
CD responded to the first infusion of  infliximab and with 
adalimumab 24%-36% of  TNF-α-antibody naïve patients 
responded to the induction of  therapy[7,8]. 
There are a few studies exploring immunological 
markers that reflect treatment response to anti-TNF-α 
therapy in CD. Elevated concentration of  mucosal nuclear 
NFκBp65 and high secretion of  TNF-α by cells of  pe-
ripheral blood cultivation precede clinical relapse[10]. In 
the study by Mäkitalo et al[11], the expression profile of  the 
macrophage tissue inhibitor of  metalloproteinase (TIMP)-1 
and stromal TIMP-3 in the intestine correlated positively 
with the Crohn’s disease endoscopic index of  severity 
(CDEIS) and the down regulation of  matrix metallopro-
teinase-9 (MMP9) production of  macrophages correlated 
with histological improvement during anti-TNF-α therapy. 
Further, in another study serum MMP9 levels seemed to 
decrease particularly in those CD patients who responded 
to infliximab therapy[12]. 
Recently, we described a novel approach to study in-
dividual treatment responses at an early phase of  gluco-
corticoid therapy. In that study we investigated pediatric 
patients with inflammatory bowel disease (IBD) intro-
duced to systemic glucocorticoids and showed that pa-
tient serum modified the expression of  T-cell signalling 
markers on target cells (peripheral blood mononuclear 
cells from a healthy donor)[13]. 
Encouraged by this finding we applied the same meth-
od to study the individual immune-activation potency in 
adult CD patients starting anti-TNF therapy. We measured 
the expression of  the regulatory T-cell markers forkhead 
transcription factor 3 (FOXP3) and glucocorticoid-induced 
tumour necrosis factor receptor (GITR), and cytokines in-
terferon γ (IFNγ), interleukin-5 (IL-5) and IL-17 induced in 
the target cells by patient serum in 15 adult CD patients at 
the beginning of  anti-TNF-α therapy. We found that prior 
to anti-TNF-α therapy the ability of  patient serum to mod-
ulate the FOXP3 and GITR activation of  the target cells 
mirrored the disease activity and the individual therapeutic 
response in the gut assessed with the CDEIS. 
MATERIALS AND METHODS
Subjects
Fifteen adult patients (6 females) with established CD 
were introduced to an anti-TNF-α agent due to an acute 
flare (n = 6), chronic active disease (6), or rapid postopera-
tive reoccurrence of  the disease (3; Table 1). Fourteen pa-
tients received infliximab infusion 5 mg/kg at week 0 and 8. 
One patient received an adalimumab induction dose 80 mg 
subcutaneously (s.c.) at week 0, followed by 40 mg s.c. ev-
ery other week until week 8. After the beginning of  the 
anti-TNF-α treatment, corticosteroids were tapered off. 
All patients underwent an ileocolonoscopy before 
the introduction of  anti-TNF-α therapy (median 7 d, 
range 1-38 d) and the endoscopic assessment of  treat-
ment response was performed at week 12 (week 10 for 
the adalimumab-treated patient). The endoscopic activity 
was graded according to the CDEIS[14,15]. This score is 
based on the presence of  superficial or deep ulcerations, 
proportion of  affected and ulcerated surface, and pres-
ence of  either ulcerated or non-ulcerated stenosis in the 
terminal ileum and four segments of  the colon (right, 
transverse, left colon and sigmoid, and rectum)[14]. Clini-
cal disease activity was assessed with the Crohn’s disease 
activity index (CDAI)[16]. 
Exclusion criteria were contraindication to anti-TNF-α 
treatment, pregnancy, history of  extensive bowel resection, 
ostomy, long-term use of  nonsteroidal anti-inflammatory 
drugs, or perianal fistulating disease without luminal in-
flammation.
Blood samples and fecal calprotectin
A serum sample for the target cell assay was provided at 
the time of  the first ileocolonoscopy. The routine blood 
samples for serum C-reactive protein (CRP, normal value 
< 10 mg/L), erythrocyte sedimentation rate (ESR) and 
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Table 1  Patient characteristics
Age (yr): median (range)   25 (19-44)
Disease duration, years median (range)  5.1 (0.4-27) 
No. of patients %
Disease location
   Ileum 2 13
   Colon 4 27
   Ileocolon 9 60
Disease type
   Inflammatory 7 47
   Stricturing 5 33
   Inflammatory + perianal 3 20
Prior anti-TNF-therapy 4 27
Prior  bowel operation 4 27
Smokers 7 47
Baseline concomitant medication 
   Azathioprine/6-mercaptopurine 10 67
   Methotrexate 2 13
   Corticosteroids 10 67
   Mesalamine or sulphasalazine 13 87
Week 12 concomitant medication
   Azathioprine/6-mercaptopurine 13 87
   Methotrexate 2 13
   Corticosteroids 1      6.7
   Mesalamine or sulphasalazine 11 73
CDAI at baseline, median (range) 158 (49-605)
CDAI at week 12, median (range)   66 (24-202)
CDAI: Crohn’s disease activity index; TNF: Tumor necrosis factor.
fecal samples for measurement of  calprotectin (PhiCal 
Test, Calpro AS, Oslo, Norway[17,18]) were obtained by 
the time of  the endoscopies and 3 mo after the first anti-
TNF-α dose[15]. 
Laboratory assay for systemic immunological effects 
The assay for the assessment of  individual stages of  im-
munoactivation by applying patient serum in an in vitro 
culture of  donor derived peripheral blood mononuclear 
cells (PBMC, target cells) is described recently in detail[13]. 
In brief, healthy donor (male 34 years) derived PBMC 
were separated by Ficoll-Paque (Amersham Biosciences) 
centrifugation (800 × G, 25 min) and cultured in the pres-
ence of  the patients inactivated (35 min in 56℃) serum at 
an end concentration of  8%, either at resting state or ac-
tivated with mitogen phytohemagglutin (PHA, 5 μg/mL). 
Serum of  a healthy donor (male 27 years) was used as the 
methodological control between cell culture plates. After 
72 h incubation at 37℃ in humified atmosphere with 
5% CO2/air the supernatants were collected and stored 
at -70℃. This assay was performed with serum samples 
drawn prior to first anti-TNF-α infusion.
ELISA for IFNγ, IL-5 and IL-17
IFNγ, IL-5 and IL-17 were measured with ELISA in du-
plicate from the supernatants collected from the target cell 
cultures (see above) incubated with patient serum. IFNγ 
and IL-5 was detected as described before[19,20]. IL-17 was 
measured according to the manufacturer’s protocol (Cata-
logue no: DY317; R&D Systems, United Kingdom). We 
subtracted the non-stimulated value from the stimulated 
value to obtain the ∆-value for statistical analyses. 
Quantitative reverse transcriptase-polymerase chain 
reaction
Quantitative reverse transcriptase-polymerase chain reac-
tion (RT-PCR) process was recently described in detail[13]. 
Briefly, total RNA was isolated from cell samples with the 
GenElute Mammalian total RNA miniprep kit (Sigma-
Aldrich), and the RNA concentration was measured by 
a spectrophotometer (ND-1000, NanoDrop Technolo-
gies Inc, Wilmington, DE, USA). Reverse transcription 
was performed by using TaqMan Reverse Transcription 
reagents (Applied Biosystems, Foster City, CA, USA) with 
additional treatment of  total RNA at 10 ng/μL with DN-
Ase I (0.01 U/μL) (Roche Diagnostics, Mannheim, Ger-
many) to eliminate genomic DNA. Quantitative RT-PCR 
was performed using predesigned FAM-labelled TaqMan 
Gene Expression Assay reagents (Applied Biosystems) 
and the ABI Prism 7700 Sequence Detection System (Ap-
plied Biosystems) in triplicate wells. Assay reagents for 
FOXP3 (Hs00203958_m1), GITR (Hs00188346_m1), 
IFNγ (Hs00174143_m1) and 18s RNA (Hs99999901_s1) 
were used. The difference value (ΔCt) is the normalised 
quantitative value of  the expression level of  the target 
gene achieved by subtracting the Ct value of  the refer-
ence gene (18s) from the Ct value of  the target gene. An 
exogenous cDNA pool calibrator was collected from 
PHA stimulated PBMC and considered as an interassay 
standard to which normalized samples were compared. 
ΔΔCt is the difference between the ΔCt of  the analyzed 
sample and ΔCt of  the calibrator. Calculation of  2-ΔΔCt 
gives a relative amount of  the target gene in analyzed 
sample compared with the calibrator, both normalized to 
an endogenous control (18S). For presentations the rela-
tive amount of  target genes was multiplied by 1000 and 
expressed as relative units.
Statistical analysis 
Results are reported as median. Comparison between two 
dependent samples was calculated with Wilcoxon rank test 
and two independent samples was calculated with Mann-
Whitney t-test. The two-tailed Spearman’s rho was used 
for calculation of  the correlations and Kruskall-Wallis test 
served in exploring associations between groups (SPSS 
16.0 program). P < 0.05 was set for statistical significance. 
Ethics
All patients gave their informed written consent for par-
ticipation in this study approved by the ethics committee 
of  the Helsinki University Central Hospital. 
RESULTS
Patient serum induced IFNγ , FOXP3 and GITR specific 
mRNA expression and secretion of IFNγ, IL-5 and IL-17 
from target cells 
The expression levels of  IFNγ, FOXP3 and GITR spe-
cific mRNA in both resting and activated target cells 
cultured in the presence of  CD patient serum obtained 
before anti-TNF-α therapy is shown in Table 2. Also, the 
secretion of  IFNγ, IL-5 and IL-17 from activated target 
cells is shown in Table 2. The secretion of  IFNγ, IL-5 and 
IL-17 from resting target cells was below detection limits.
The type of  CD or localization was not associated 
with the level of  IFNγ, FOXP3 and GITR specific 
mRNA expression or IFNγ, IL-5 and IL-17 secretion 
from target cells (all P = NS).
CDEIS
During anti-TNF-α therapy the CDEIS decreased from 
a median of  13 points (range 1.8-25) to 4.8 points (range 
0-11, P = 0.002). 12/15 patients responded to therapy, 
while 3 patients had no decrease in the CDEIS.
Correlations between the target cell responses and pre-
treatment the CDEIS 
The expression of  regulatory T-cell markers FOXP3 and 
GITR specific mRNA in activated target cells cultured 
with patient serum correlated inversely with the pre-treat-
ment CDEIS (FOXP3 r = -0.621, P = 0.013 and GITR r 
= -0.625, P = 0.013; Figure 1). A trend towards an inverse 
correlation between IFNγ mRNA expression and the pre-
treatment CDEIS was observed (r = -0.446, P = 0.095). 
There was no correlation between IFNγ, IL-5 or IL-17 
secretion from target cells and the pre-treatment CDEIS (P 
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= 0.241 for IFNγ, P = 0.286 for IL-5 and P = 0.980 for 
IL-17).
Correlations between target cell responses and the 
change of CDEIS during anti-TNF-α therapy
Low patient serum induced FOXP3, GITR and IFNγ 
specific mRNA expression in target cells was associated 
with a remarkable change of  CDEIS observed during 
3 mo therapy (FOXP3 r = -0.600, P = 0.018; GITR r = 
-0.589, P = 0.021; IFNγ r = -0.486, P = 0.066; Figure 2). 
Accordingly, in resting target cells GITR specific mRNA 
expression correlated with the change of  CDEIS (r = 
-0.550, P = 0.034). 
Also low serum induced IFNγ and IL-5 secretion 
from activated target cells was associated with a high 
change of  CDEIS (r = -0.538, P = 0.039; r = -0.504, P = 
0.055). IL-17 secretion from activated target cells did not 
correlate with the change of  CDEIS (P = 0.467).
 
Findings related to fecal calprotectin 
Fecal calprotectin decreased from a median of  1170 μg/g 
(range 88-15300) to a median of  130 μg/g (range 13-1400) 
within the 3 mo anti-TNF-α treatment (P = 0.001). No 
correlation was observed between target cell responses and 
calprotectin levels before or after treatment.
Findings related to ESR and CRP
ESR decreased from a median of  18 mm/h (range 6-58) 
to a median of  10.6 mm/h (range 1-40; P = 0.001) and 
CRP decreased from a median of  10 mg/L (range 0-54) 
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Table 2  The effect of Crohn's disease patient serum withdrawn before anti-tumor necrosis factor-α therapy on forkhead transcription 
factor 3, glucocorticoid-induced tumour necrosis factor receptor and interferon γ specific mRNA expression (relative units) and 
interferon γ, interleukin-5 and interleukin-17 secretion (pg/mL) from peripheral blood mononuclear cells obtained from healthy 
volunteers (target cells)
RT-qPCR ELISA 
Patient No. FOXP3 FOXP3 PHA GITR GITR PHA IFNγ IFNγ PHA IFNγ PHA IL-5 PHA IL-17 PHA
1 4.9 53.8 10.8 65.0 1.8 11.7 1580.0 8.4 0.0
2 8.2 65.4 18.7 175.9 3.8 30.5 37 400.0 80.5 19.4
3 12.9 127.7 30.8 452.9 11.6 128.9 172 000.0 187.0 239.0
4 9.2 153.7 32.5 399.2 5.0 52.0 97 600.0 154.0 265.0
5 10.0 68.4 22.8 183.2 8.2 22.6 38 100.0 81.5 118.0
6 4.0 4.6   8.9 55.2 1.3 10.4 0.0 0.5 42.7
7 11.5 36.7 22.4 107.0 6.1 19.3 1460.0 8.5 20.9
8 7.9 97.0   17.93 171.0 5.8 26.2 0.0 6.5 82.0
9 4.6 40.7   9.3 66.6 3.0 4.5 0.0 1.0 0.0
10 6.4 68.3 15.8 145.8 4.2 15.8 28.8 4.1 0.0
11 7.4 96.9 17.0 251.4 3.4 36.1 173.0 7.4 0.0
12 6.9 86.4 15.1 217.4 4.3 36.2 223 000.0 144.0 638.0
13 5.2 32.7 14.1 83.0 3.8 5.3 11 600.0 3.3 341.0
14 3.8 81.6 12.7 180.7 2.9 13.5 1660.0 0.5 181.0
15 5.4 31.2   9.9 54.4 3.6 3.3 16 100.0 5.5 310.0
Secretion of interferon (IFN) γ, interleukin (IL)-5 and IL-17 from naive target cells was below detection limit. Phytohemagglutin (PHA) = Target cells activated 
with phytohemagglutin. RT-qPCR: Quantitative reverse transcriptase-polymerase chain reaction; GITR: Glucocorticoid-induced tumour necrosis factor 
receptor; FOXP3: Forkhead transcription factor 3.
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Figure 1  Patient serum withdrawn before anti-tumor necrosis factor-α therapy induced forkhead transcription factor 3 (A) and glucocorticoid-induced 
tumour necrosis factor receptor (B) specific mRNA expression (relative units) in activated target cells that correlated negatively with pre-treatment Crohn's 
disease endoscopic index of severity. [points; forkhead transcription factor 3 (FOXP3) r = -0.621, P = 0.013; glucocorticoid-induced tumour necrosis factor receptor 
(GITR) r = -0.625, P = 0.013]. Patients who had no decrease in Crohn's disease endoscopic index of severity (CDEIS) during therapy are marked with star.
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to a median of  < 5 mg/L (range < 5-11, P = 0.005) with-
in 3 mo after introduction of  anti-TNF-α therapy.
FOXP3 specific mRNA expression in activated target 
cells correlated negatively with pre-treatment ESR (r = 
-0.548, P = 0.034, Figure 3). There was no correlation 
between pre-treatment ESR and GITR (P ≥ 0.210) or 
IFNγ (P ≥ 0.109) specific mRNA expression or cytokine 
secretion from target cells (IFNγ P = 0.755, IL-5 P = 0.434, 
IL-17 P = 0.511).
FOXP3, GITR or IFNγ specific mRNA expression in 
target cells or IFNγ, IL-5 or IL-17 secretion from target 
cells did not correlate with the change of  ESR or CRP 
during 3 mo anti-TNF-α therapy (all P = NS, data not 
shown).
DISCUSSION
We found that serum samples obtained from patients with 
CD before the introduction of  anti-TNF-α therapy mod-
ulated the expression of  regulatory T-cell (T-reg) markers 
FOXP3 and GITR and secretion of  inflammatory cyto-
kines IFNγ, IL-5 and IL-17 from target cells (peripheral 
blood mononuclear cells from healthy donors). The serum 
induced FOXP3, GITR and IFNγ responses of  target 
cells correlated with the pre-treatment endoscopic status 
and also with therapeutic responses, i.e. mucosal improve-
ment assessed with CDEIS within 3 mo.
In our previous study of  children with IBD we found 
that the attenuation of  systemic inflammation after the 
start of  oral glucocorticoids was mirrored in the target cell 
responses induced by the patient serum[13]. We underline 
that we measured cytokine secretion and transcription 
markers of  the target cells (donor derived PBMCs) modu-
lated by the patient serum and not the activation stage of  
the PBMC from the patient. To our knowledge the ability 
of  patient serum to activate signalling of  normal T-cells 
has not previously been studied in adult CD patients at 
induction of  anti-TNF-α therapy. It is remarked that 
post-treatment samples are not comparable here since the 
serum taken after the treatment contains an anti-TNF-α 
agent.
We found an inverse correlation between the expression 
of  T-reg markers FOXP3 and GITR in target cells and the 
endoscopic disease activity before therapy. A similar inverse 
correlation existed also between FOXP3 and pre-treatment 
ESR. Since FOXP3 inhibits T-cell activation by its suppres-
sive effect on transcription of  cytokine genes[21] it is reason-
able to assume that those patients whose serum environ-
ment seemed to mediate enhanced FOXP3 up-regulation 
as a response to T-cell stimulation had endoscopically 
milder disease. However, the serum induced expression of  
FOXP3 in target cells was not directly reflected in the cyto-
kine activation of  the target cells and cytokine response did 
not correlate with the pre-treatment CDEIS. Impaired up-
regulation of  GITR in the patient serum environment may 
be related to poor suppression of  T-cell activation[22,23]. 
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Figure 2  Patient serum withdrawn before anti-tumor necrosis factor-α therapy induced (A) forkhead transcription factor 3 (r = -0.600, P = 0.018) and (B) 
glucocorticoid-induced tumour necrosis factor receptor (r = -0.589, P = 0.021) specific mRNA expression (relative units) in activated target cells that had a 
negative correlation with the change of Crohn’s disease endoscopic index of severity during three months therapy. The change of Crohn’s disease endoscopic 
index of severity (CDEIS) corresponds with the decrease in points along improvement and is given as a positive value to illustrate the magnitude of therapeutic response. 
Patients who showed no decrease in the CDEIS during therapy are marked with star. GITR: Glucocorticoid-induced tumour necrosis factor receptor; FOXP3: Forkhead 
transcription factor 3.
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Figure 3  Patient serum withdrawn before anti-tumor necrosis factor-α 
therapy induced forkhead transcription factor 3 specific mRNA expression 
(relative units) in activated target cells that correlated negatively with eryth-
rocyte sedimentation rate. ESR: Erythrocyte sedimentation rate. r = -0.548, P = 
0.034.
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Interestingly, we also found that low expression of  
FOXP3 and GITR specific mRNA induced by patient se-
rum obtained prior to therapy was associated with a good 
therapeutic response within 3 mo. These parameters were 
associated with high clinical activity and thus enhanced 
inflammation in vivo. High inflammatory activity at the 
early phase of  anti-TNF-α therapy has been connected 
to the lack of  therapeutic response in rheumatoid arthritis 
(RA). Previously non-responders to anti-TNF-α agents 
had a higher number of  blood T-cells expressing chemo-
kine receptors (CCR 3 and CCR 5) before the introduc-
tion of  therapy[24]. In another study, high levels of  serum 
IL-2 were associated with poor therapeutic response[25]. 
In our study, the group of  patients that had high potency 
for FOXP3 induction in target cells showed poor clinical 
response to anti-TNF treatment. It was also evident that 
their disease activity before treatment was milder. TNF 
blocking has been shown to induce FOXP3 expression in 
patients with RA. Recovery of  regulatory mechanisms has 
been proposed to be one of  the mechanisms of  action 
for TNF blocking[26]. It is possible that non-responders 
whose serum induced high FOXP3 up-regulation in target 
cells do not benefit from further activation of  FOXP3 but 
their disease activity should be down-regulated by other 
mechanisms.
The majority of  CD patients driven to anti-TNF-α 
therapy are on immunosuppressive medication such as 
azathioprine or methotrexate as here also. However, there 
was no correlation between patient serum induced expres-
sion or secretion of  inflammatory cytokines from target 
cells and pre-treatment disease activity. We suggest that 
individual differences in target cell responses mediated by 
patient serum represents the net effect of  maintenance 
medication, disease activity and patients immunological 
heterogeneity that together reflect the patients further ca-
pability to respond to biological therapy. 
Fecal calprotectin correlates with the CDEIS and 
CRP[15,27]. In this study we failed to find statistically signifi-
cant correlations between calprotectin or CRP and target 
cell responses. This finding was similar to the finding in our 
previous study of  IBD children. Fecal calprotectin excre-
tion reflects increased neutrophils and mononuclear cell mi-
gration into the gut lumen through the inflamed mucosa[28] 
and CRP is an acute phase protein produced predominantly 
in the liver in response to stimulation by IL-6, TNF-α and 
IL-1β[29]. It seems that the ability of  patient serum to ac-
tivate target cells reflects the immunological net effects in 
circulation in CD patients rather than inflammatory cell ac-
cumulation in the intestine reflected in fecal calprotectin.
To conclude, there are few studies of  the mechanisms 
of  treatment failure during anti-TNF-α therapy. An im-
paired response to anti-TNF-α therapy in CD has been 
suggested to be a result of  early reactivation of  the inflam-
matory cascade caused by individual intrinsic immunologi-
cal mechanisms[10]. Also the inflammatory activity of  the 
disease itself  may play a role in the therapeutic response. 
We found that the immune activation potency of  the pa-
tient serum that is monitored by gene expression profile 
of  human PBMC is individual and correlates to later mu-
cosal healing during anti-TNF-α therapy. Characterization 
of  the key factors in serum that mediated the effects ob-
served with this method, such as up-regulation of  FOXP3 
and GITR, could be one step toward better understanding 
of  in vivo actions of  anti-TNF-α therapies. 
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COMMENTS
Background
Since the FDA approval of infliximab in 1999 for the treatment of severe Crohn’s 
disease (CD), the use of tumor necrosis factor-α (TNF-α)-antagonist agents has 
emerged in treatment of severe inflammatory bowel disease. A significant propor-
tion of patients, however, do not respond to the treatment. To date there are no 
means to foresee the therapeutic response or to monitor the response at an early 
phase of therapy with an TNF-α-antagonist agent.
Research frontiers
Recently, the authors applied a novel immunological assay for assessment of 
therapeutic response to glucocorticoids in pediatric patients with inflammatory 
bowel disease. In that study they showed that the therapeutic effect of cortico-
steroid therapy can be measured from patient serum at an early phase of the 
therapy. In the in vitro assay, a sample of patient serum is used to stimulate hu-
man white blood cells and the effect on specific white blood cell (T cell) markers 
is assessed. This kind of testing seems a promising means to predict individual 
responses to immunological therapies.
Innovations and breakthroughs
There are few studies exploring the immunological markers that reflect treat-
ment response to anti-TNF-α therapy in CD. Here the authors used a recently 
described assay to measure therapeutic response to TNF-α-antagonist therapy 
from a patient serum sample. Disease activity and response to therapy is 
reflected in the patient serum and can be measured before the introduction of 
therapy. Serum induced changes in the specific white blood cell markers [fork-
head transcription factor 3 (FOXP3), glucocorticoid-induced tumour necrosis 
factor receptor (GITR)] seemed to reflect individual response to anti-TNF-α 
therapy. 
Applications 
The results suggest that the effect of therapy with an anti-TNF-α agent can be 
measured from patient serum at an early phase. The study group was small 
and the results are preliminary, thus more studies are warranted to establish 
whether this kind of serum testing is suitable for predicting the individual re-
sponse to anti-TNF-α therapy in clinical practice. 
Terminology
Forkhead box P3, FOXP3, is a gene regulating the development and function 
of specific white cells, regulatory T cells. GITR is glucocorticoid-induced tumour 
necrosis factor receptor. FOXP3 and GITR are commonly used markers for 
regulatory T-cell activity. 
Peer review
This study raises some interesting points never raised before about the T regu-
latory cell responses with biological agents. 
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